Frost & Sullivan Independent Equity Research
RedHill Biopharma Ltd.: The acceleration of RHB-104 Phase III Study in Crohn’s disease increases company value and share price.
![redhill redhill](https://www.frostequityresearch.com/wp-content/uploads/elementor/thumbs/redhill-nx7oeooppwzdf81hcfxh8nobo63au3cco6m1rxg31y.png)
Company: RedHill Biopharma
Sector: Pharmaceuticals
Report type: Immediate Report
Published on: October 15, 2017